Nihal Piskin

Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia.

The aim of this study was to compare the responses of colistin treatment alone vs. a combination of colistin and rifampicin in the treatment of ventilator-associated pneumonia (VAP) caused by a carbapenem-resistant A. baumannii strain. Forty-three patients were randomly assigned to one of two treatment groups. Although clinical (P = 0·654), laboratory (P = 0·645), radiological (P = 0·290) and microbiological (P = 0·597) response rates were better in the combination group, these differences were not significant. However, time to microbiological clearance (3·1 ± 0·5 days, P = 0·029) was significantly shorter in the combination group. The VAP-related mortality rates were 63·6% (14/22) and 38·1% (8/21) for the colistin and the combination groups (P = 0·171), respectively. Our results suggest that the combination of colistin with rifampicin may improve clinical and microbiological outcomes of VAP patients infected with A. baumannii.

Inadequate treatment of ventilator-associated and hospital-acquired pneumonia: Risk factors and impact on outcomes

BackgroundInitial antimicrobial therapy (AB) is an important determinant of clinical outcome in patients with severe infections as pneumonia, however well-conducted studies regarding prognostic impact of inadequate initial AB in patients who are not undergoing mechanical ventilation (MV) are lacking. In this study we aimed to identify the risk factors for inadequate initial AB and to determine its subsequent impact on outcomes in both ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP).MethodsWe retrospectively studied the accuracy of initial AB in patients with pneumonia in a university hospital in Turkey. A total of 218 patients with HAP and 130 patients with VAP were included. For each patient clinical, radiological and microbiological data were collected. Stepwise multivariate logistic regression analysis was used for risk factor analysis. Survival analysis was performed by using Kaplan-Meier method with Log-rank test.ResultsSixty six percent of patients in VAP group and 41.3% of patients in HAP group received inadequate initial AB. Multiple logistic regression analysis revealed that the risk factors for inadequate initial AB in HAP patients were; late-onset HAP (OR = 2.35 (95% CI, 1.05-5.22; p = 0.037) and APACHE II score at onset of HAP (OR = 1.06 (95% CI, 1.01-1.12); p = 0.018). In VAP patients; antibiotic usage in the previous three months (OR = 3.16 (95% CI, 1.27-7.81); p = 0.013) and admission to a surgical unit (OR = 2.9 (95% CI, 1.17-7.19); p = 0.022) were found to be independent risk factors for inadequate initial AB. No statistically significant difference in crude hospital mortality and 28-day mortality was observed between the treatment groups in both VAP and HAP. However we showed a significant increase in length of hospital stay, duration of mechanical ventilation and a prolonged clinical resolution in the inadequate AB group in both VAP and HAP.ConclusionOur data suggests that the risk factors for inadequate initial AB are indirectly associated with the acquisition of resistant bacteria for both VAP and HAP. Although we could not find a positive correlation between adequate initial AB and survival; empirical AB with a broad spectrum should be initiated promptly to improve secondary outcomes.

Platelet and mean platelet volume kinetics in adult patients with sepsis

Abstract The aims of this study were to evaluate the kinetics of platelet counts and mean platelet volume (MPV) in adults with sepsis and to determine whether the responses are infection-specific. This retrospective cohort study included patients admitted to a tertiary-care teaching hospital with microbiologically proven nosocomial sepsis between January 2006 and January 2011. Platelet counts and MPV measurements were examined daily for 5 days after the onset of sepsis. During the study period, 151 of the 214 sepsis episodes were associated with thrombocytopenia. Gram-positive microorganisms were the most frequently isolated. The decrease in platelet counts was statistically significant for the first 3 days of sepsis in Gram-positive septic patients, for 4 days in Gram-negative septic patients and for all 5 days in fungal septic patients (p < 0.001). The increase in MPV values was statistically significant for the first 3 days of sepsis in Gram-positive septic patients and for all 5 days in the other groups (p < 0.001). We conclude that fungal sepsis has a stronger association with thrombocytopenia and increased MPV.

Piperacillin–tazobactam Versus Carbapenem Therapy With and Without Amikacin as Empirical Treatment of Febrile Neutropenia in Cancer Patients: Results of an Open Randomized Trial at a University Hospital

OBJECTIVE Empirical beta-lactam monotherapy has become the standard therapy in febrile neutropenia. The aim of this study was to compare the efficacy and safety of piperacillin-tazobactam versus carbapenem therapy with or without amikacin in adult patients with febrile neutropenia. METHODS In this prospective, open, single-center study, 127 episodes were randomized to receive either piperacillin-tazobactam (4 x 4.5 g IV/day) or carbapenem [meropenem (3 x 1 g IV/day) or imipenem (4 x 500 mg IV/day)] with or without amikacin (1 g IV/day). Doses were adjusted according to renal function. Clinical response was determined during and at completion of therapy. RESULTS One hundred and twenty episodes were assessable for efficacy (59 piperacillin-tazobactam, 61 carbapenem). Mean duration of treatment was 14.8 +/- 9.6 days in the piperacillin-tazobactam group and 14.7 +/- 8.8 days in the carbapenem group (P > 0.05). Mean days of fever resolution were 5.97 and 4.48 days for piperacillin-tazobactam and carbapenem groups, respectively (P > 0.05). Similar rates of success without modification were found in the piperacillin-tazobactam (87.9%) and in the carbapenem groups (75.4%; P > 0.05). Fungal infection occurrence rates were 30.5 and 18% in piperacillin-tazobactam and carbapenem groups, respectively (P = 0.05). Antibiotic modification rates were 30.5 and 13.1% (P = 0.02) and the addition of glycopeptides to empirical antibiotic regimens rates were 15.3 and 44.3% for piperacillin-tazobactam and carbapenem groups, respectively (P = 0.001). The rude mortality rates were 14% (6/43) and 29.3% (12/41) in piperacillin-tazobactam and carbapenem groups, respectively (P = 0.08). CONCLUSIONS The effect of empirical regimen of piperacillin-tazobactam regimen is equivalent to carbapenem in adult febrile neutropenic patients.

Activity of a dry mist-generated hydrogen peroxide disinfection system against methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii

BACKGROUND The aim of this study was to evaluate the activity of a dry mist-generated hydrogen peroxide (DMHP) system (Sterinis; Gloster Sante Europe, Labege cedex, France) against methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. METHODS McFarland 0.5 suspensions of 2 test bacteria, either pure or containing 5% sterile serum, were prepared and inoculated onto sterile stainless steel disks. Each disk in a Petri dish-with the Petri dish cover either closed or open-was placed in different locations in an intensive care unit room. Quantitative cultures were performed after the cycle. RESULTS No growth occurred on the disks in the absence of a barrier, except 1 disk containing serum. Existence of a barrier, as a drawer or a covered Petri dish, caused failure in the disinfection activity. The mean reduction in initial log(10) bacterial count was lower for both of the test bacteria in presence of a barrier: 4.44- to 4.70-log(10) colony-forming units (cfu) decrease was observed in absence of a barrier, whereas 1.49- to 3.79-log(10) cfu decrease was observed in presence of a barrier. When the culture results were compared according to organic load content, the mean (±standard deviation) reduction of initial contamination in pure and in serum containing MRSA suspensions was 4.25 ± 1.20- and 3.34 ± 1.89-log(10) cfu, respectively. The mean (±standard deviation) reduction in pure and in serum containing A baumannii suspensions was 4.34 ± 0.89- and 3.87 ± 1.26-log(10) cfu, respectively. The differences were statistically significant (P < .001). CONCLUSION Sterinis was capable of killing MRSA and A baumannii on open surfaces; however, it was not effective in closed or semiclosed areas. Presence of serum also caused failure in the disinfection activity of the system.

Factors associated with catheter-associated urinary tract infections and the effects of other concomitant nosocomial infections in intensive care units

Abstract Background: Catheter-associated urinary tract infections (CAUTIs) are the most common nosocomial infections in intensive care units (ICUs). The objectives of this study were to describe the incidence, aetiology, and risk factors of CAUTIs in ICUs and to determine whether concomitant nosocomial infections alter risk factors. Methods: Between April and October 2008, all adult catheterized patients admitted to the ICUs of Zonguldak Karaelmas University Hospital were screened daily, and clinical and microbiological data were collected for each patient. Results: Two hundred and four patients were included and 85 developed a nosocomial infection. Among these patients, 22 developed a CAUTI alone, 38 developed a CAUTI with an additional nosocomial infection, either concomitantly or prior to the onset of the CAUTI, and 25 developed nosocomial infections at other sites. The CAUTI rate was 19.02 per 1000 catheter-days. A Cox proportional hazard model showed that in the presence of other site nosocomial infections, immune suppression (hazard ratio (HR) 3.73, 95% CI 1.47–9.46; p = 0.006), previous antibiotic usage (HR 2.06, 95% CI 1.11–3.83; p = 0.023), and the presence of a nosocomial infection at another site (HR 1.82, 95% CI 1.04–3.20; p = 0.037) were the factors associated with the acquisition of CAUTIs with or without a nosocomial infection at another site. When we excluded the other site nosocomial infections to determine if the risk factors differed depending on the presence of other nosocomial infections, female gender (HR 2.67, 95% CI 1.03–6.91; p = 0.043) and duration of urinary catheterization (HR 1.07 (per day), 95% CI 1.01–1.13; p = 0.019) were found to be the risk factors for the acquisition of CAUTIs alone. Conclusions: Our results showed that the presence of nosocomial infections at another site was an independent risk factor for the acquisition of a CAUTI and that their presence alters risk factors.

Health-care associated bacteremia in geriatric cancer patients with febrile neutropenia.

OBJECTIVE The aim of this study was to determine the epidemiology, clinical manifestations, and outcome of health-care associated bacteremia in geriatric cancer patients with febrile neutropenia. MATERIALS AND METHODS We retrospectively evaluated cancer patients with febrile neutropenia aged ≥60years with culture proven health-care associated bacteremia between January 2005 and December 2011. The date of the first positive blood culture was regarded as the date of bacteremia onset. Primary outcome was the infection related mortality, defined as the death within 14days of bacteremia onset. RESULTS The two most common pathogens responsible for bacteremia were Staphylococcus epidermidis (36.1%) and Escherichia coli (31.5%), with high rates of methicillin resistance and extended-spectrum β-lactamase (ESBL) production, respectively. There were no statistically significant differences in infection related mortality rate according to the type of malignancy (p=0.776). By the univariate analysis, factors associated with 14day mortality among febrile neutropenic episodes were prolonged neutropenia (p=0.024), persistent fever (p=0.001), hospitalization in ICU (p<0.001) and the initial clinical presentations including respiratory failure (p<0.001), hepatic failure (p=0.013), hematological failure (p<0.001), neurological failure (p<0.001), severe sepsis (p<0.001), and septic shock (p=0.036). Multivariate analysis showed that persistent fever was an independent factor associated with infection related mortality (odds ratio, 18.0; 95% confidence interval, 5.2-62.6; p<0.001). CONCLUSIONS The only independent risk factor for mortality was persistent fever. Although the most frequently isolated pathogens were S. epidermidis and E. coli, high rates of methicillin resistance and ESBL production were found respectively.

Herpes simplex virus encephalitis in pregnancy

Herpes simplex encephalitis (HSE), which is an uncommon condition, is a significant cause of neurological impairment in pregnant women. Assessment of fetal contamination remains a problem. Up to now only a few pregnant HSE cases have been reported in the literature [1]. We report a case of HSE in the third trimester of pregnancy who was treated with acyclovir and recovered completely to deliver a healthy child at term. A 26-year-old woman, gravida 1 para 0, at 25 weeks of gestation was admitted to our hospital with a five-day history of fever, headache, and nausea and a 12-hour history of mental status changes. Her symptoms were initially attributed to acute sinusitis, and cefuroxime axetil p.o. had been started four days previously. The day before admission she had begun to display personality changes and abnormal behaviors. On admission, her blood pressure was 140/90 mmHg and her temperature was 398C. Physical and neurological examinations were unremarkable and signs of meningeal irritation were absent. Her laboratory test results were as follows: leukocyte count 156 10/mm, hemoglobin 10.2 g/dL, C-reactive protein þ, erythrocyte sedimentation rate 31 mm/h; platelet count, blood biochemistry tests, and urinalysis were normal. Lumber puncture (LP) was performed, which showed normal cerebrospinal fluid (CSF) pressure, with 70 white cells (90% polymorphonuclear cells) and 40 red cells per mm. CSF protein was 51.66 mg/dL, CSF glucose was 64.36 mg/dL, and blood glucose was 134 mg/dL. Acid-fast and Gram stains revealed no positive results. An initial diagnosis of poorly treated bacterial meningitis and encephalitis was made and ceftriaxone 26 2 g i.v. and acyclovir 36 750 mg i.v. was started. On the second day of admission she suffered a generalized tonic-clonic epileptic seizure and phenytoin therapy was added. CSF culture was negative. On follow-up she remained febrile and her conscious state deteriorated, hence on day 3, ceftriaxone was ceased and meropenem 36 2 g i.v. was started in addition to acyclovir. An electroencephalogram (EEG) showed diffuse slowing with an epileptic activity in the right frontal region. On the same day, a cerebral magnetic resonance imaging (MRI) was performed showing increased signal and edema in the right temporal region. Dexamethasone therapy was started. On day 5 she became afebrile but remained drowsy over the following two days. On day 7 her conscious state improved and the results of the herpes simplex virus (HSV) type I polymerase chain reaction (PCR) on the initial CSF sample was positive confirming the diagnosis of HSE. She had no evidence of genital or disseminated HSV infection. HSV type I and type II IgM and HSV type II IgG were negative, and HSV type I IgG was positive in serum. Meropenem was ceased and the patient received a 21-day course of acyclovir with a rapid improvement in her condition. During the course of the disease, fetal ultrasound monitoring was normal. Dexamethasone was continued in a reducing regimen until day 28. One week after discharge, a control EEG showed normal